Robot model
Genesis RMN / GenesisX
Stereotaxis (NYSE American: STXS; headquartered in St.
- Manufacturer
- Stereotaxis
- Form factor
- surgical
- Maturity
- commercial
- Lifecycle
- active
- Deployments
- 1
Overview
Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.
Verified vs. claimed
- Maturity stage
- commercial(Commercially deployed with revenue-generating operations.)
- Verified deployments
- 1 deployment on file
- Sources on file
- 4 sources, view all
Key facts
Installed base
CE mark
FDA clearance
FDA approval
Q1 2026 system revenue
Specs
Notes
Products
Form Factor
Fda clearance
Clearance body
Procedure types
Data & sources
Press releases
3
Web sources
1
4 sources backing this record.View all →
Pricing
No verified price is on record for Genesis RMN / GenesisX. Physical-AI systems are often sold through enterprise contracts or operated as a service rather than at a public list price.
Deployments (1)
- Genesis RMN / GenesisX at United Statesoperational
Genesis RMN / GenesisX on the deployment map
Where Genesis RMN / GenesisX is verified operating. Explore the deployment map by place and type.
Recent activity
Every change to this record is dated, sourced, and independently verified where marked.
- Verified media addedVerifiedJun 5, 2026
Stereotaxis Genesis robotic magnetic navigation
- Record createdJun 3, 2026
Added to the verified registry
- Price point recordedJan 1, 2024
Not announced
- Deployment verifiedVerifiedJan 1, 2019
at United States
Deployment-verified media (1)
Stereotaxis' introduction of its Genesis Robotic Magnetic Navigation system. This is robotic magnetic navigation for catheter-based cardiac electrophysiology (endovascular), a different modality from laparoscopic surgery.
From deployment: United States
Regulatory filings (2)
- fda_510kfda 510k · us_fdacleared
- fda_510kfda 510k · us_fdacleared2024-01-01
Applicant: Stereotaxis
Safety record
No incidents on record for Genesis RMN / GenesisX.
Only active incidents are counted. Retracted incidents are excluded from this summary but remain reachable at their canonical URLs.
Sources (4)
Common questions
- What is Genesis RMN / GenesisX?
- Stereotaxis (NYSE American: STXS; headquartered in St. Louis, Missouri) pioneered Robotic Magnetic Navigation, a distinct surgical-robot modality in which two large external magnets robotically steer a magnetic-tipped catheter inside the heart for catheter-based electrophysiology and cardiac ablation. It is genuinely a robot, with computer-controlled physical actuation of an in-body instrument, but an unusual one whose manipulator is the magnetic field acting on a soft catheter rather than a rigid arm, placing it in a distinct endovascular sub-category rather than the soft-tissue laparoscopic mainstream. Its current-generation Genesis RMN system succeeded the legacy Niobe, the next-generation small-footprint GenesisX received its European CE mark in August 2024 and US FDA 510(k) clearance on November 10, 2025, and the MAGiC magnetic ablation catheter that the system steers received FDA approval on January 6, 2026, with the first US procedure performed at OHSU. The registry records it at commercial maturity, with more than 100 RMN systems installed across about 31 countries, public-company revenue, and GenesisX in early limited launch, and notes that the company signed an agreement to acquire the endovascular-robotics firm Robocath in early 2026. A correction to the dispatch framing: no Stereotaxis product named Mavericks exists in any primary source, and the real third leg of the portfolio is the MAGiC ablation catheter, so Mavericks is not recorded. The figure of more than 140,000 cumulative patients is a company marketing figure, and exact current GenesisX install counts beyond a first installation and limited launch are not verified.
- How much does Genesis RMN / GenesisX cost?
- Genesis RMN / GenesisX's price is not publicly disclosed. DEPLOY has no verified price on record for Genesis RMN / GenesisX from Stereotaxis. Physical-AI systems like this are often sold through enterprise contracts or operated as a service rather than at a public list price; check the manufacturer for the latest.
- Is Genesis RMN / GenesisX actually deployed in the real world?
- Yes. Genesis RMN / GenesisX is independently verified in real-world operation on the DEPLOY registry, confirmed at named deployment sites with primary sources: not a concept, render, or demo-only.
- Who makes Genesis RMN / GenesisX?
- Genesis RMN / GenesisX is made by Stereotaxis, based in St. Louis, MO, USA, founded in 1990.
- Where is Genesis RMN / GenesisX deployed?
- 1 verified deployment of Genesis RMN / GenesisX is on the DEPLOY registry, including at United States.
- Can you buy Genesis RMN / GenesisX?
- Genesis RMN / GenesisX is in commercial deployment and is sold to operators; contact the manufacturer to buy, and see the pricing section for any recorded price.
- Is Genesis RMN / GenesisX FDA cleared?
- Genesis RMN / GenesisX has 2 regulatory records on the DEPLOY registry: FDA 510(k) clearance, cleared; FDA 510(k) clearance, cleared. See the Regulatory filings section for each agency source.
- What are alternatives to Genesis RMN / GenesisX?
- On the DEPLOY registry, comparable surgical robots to Genesis RMN / GenesisX include Toumai, da Vinci (and Ion), Epione, Hugo RAS.
- How does Genesis RMN / GenesisX compare to Toumai?
- Genesis RMN / GenesisX and Toumai (MicroPort MedBot · 8 deployments) are both surgical robots on the DEPLOY registry. Genesis RMN / GenesisX has 1 verified deployment on record. Compare both records for specs, safety, deployments, and verified-vs-claimed autonomy.
- Is Genesis RMN / GenesisX a top surgical?
- On DEPLOY's intelligence score, which blends verified deployments, safety, adoption, media, and IP signals, Genesis RMN / GenesisX ranks in roughly the top 42% of surgical models tracked by the registry.
- What is Genesis RMN / GenesisX's maturity stage?
- Genesis RMN / GenesisX is at the commercial stage on the DEPLOY maturity ladder (research, prototype, pilot, commercial, production). Commercial stage means production-grade deployments are operating at named customer sites.
- Is Genesis RMN / GenesisX safe?
- Genesis RMN / GenesisX has no incidents on record in the DEPLOY registry. This does not constitute a safety guarantee; it reflects the incidents DEPLOY has tracked and verified to date.
Methodology: Verified · 4 sources (3 primary) · last reviewed 2026-07-12
Verification posture
Verified
High confidence
Review state
Stable
Last reviewed 2026-07-12
Maturity + lifecycle
Maturity stage: commercial
Lifecycle: active
Architectural position
Cohort: surgical
Sources by quality tier
- 3
- primary-company-ir
- Company IR disclosure
- 1
- knowledge-base
- Knowledge base
The framework is documented at /methodology. Corrections at /corrections. Reviewer: DEPLOY editorial team.
Methodology surface for Genesis RMN / GenesisX.Recent coverage
Genesis RMN / GenesisX in third-party press
Attention vs reality over time
Media mentions per month (area) against verified deployment events (dots). A press spike over a flat deployment line is the hype gap, drawn over time.
In the press
Recent coverage mentioning Genesis RMN / GenesisX from third-party publications. Automatically surfaced; not part of the verified registry record.
Stereotaxis Next-Gen Endovascular Surgical Robot Receives 510k Clearance from FDA
Stereotaxis received FDA 510(k) clearance for its next-generation endovascular surgical robot, advancing minimally invasive cardiac procedures.
Stereotaxis Expands Endovascular Reach with 5M Robocath Acquisition
Stereotaxis acquired Robocath for 5M to expand its endovascular robotic surgery reach.
Stereotaxis Earns FDA Clearance and Announces U.S. Launch of Genesis
Stereotaxis received FDA clearance for the Genesis RMN system, a leap forward in Robotic Magnetic Navigation technology for cardiac procedures.
Machine-readable surfaces
- Markdown mirror: /models/stereotaxis-genesis.md
- JSON-LD: embedded in this page’s head
- REST API: /v1/models/eca99ad0-d6db-401f-9575-6e22a77bfc14
- Revision history: /models/stereotaxis-genesis/history
- Data documentation: /data
- Query this programmatically: Deploy MCP
Reality vs attention
Genesis RMN / GenesisX draws attention at the 16th percentile but verifies reality at the 23rd percentile among surgical robots. Hype Gap -7.2, 15th widest among surgical robots.
6-month trend
Analysis
Limited independent press and video coverage to date.
Signal flags
Dimension breakdown
Verified signal
Attention (reach, not merit)
DEPLOY Intelligence scores are computed from verified registry data: confirmed deployments, disclosed funding rounds, regulatory filings, active job listings, video viewership, and press coverage. Confidence ratings reflect data availability. Scores update nightly.
DEPLOY Indices — verified vs claimed
Last computed: Jul 19, 2026